Tripterygium ( DrugBank: Tripterygium )


8 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis9
66IgA nephropathy6
67Polycystic kidney disease1
96Crohn disease2
162Pemphigoid1
222Primary nephrotic syndrome8
224Purpura nephritis2
271Ankylosing spondylitis2

46. Malignant rheumatoid arthritis


Clinical trials : 4,356 Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ITMCTR2100005277
2020-07-182021-09-05Observation on the efficacy of Tripterygium wilfordii polyglycosides tablets combined with Adamumab in the treatment of rheumatoid arthritisA multicenter, prospective, observational study to evaluate the efficacy and safety of Tripterygium wilfordii polyglycosides combined with Adamumab in the treatment of rheumatoid arthritis rheumatoid arthritis1:Tripterygium wilfordii polyglycoside tablets + Adamu monoclonal antibody;2:Methotrexate tablets + Adamu monoclonal antibody ;The Second Affiliated Hospital of Guizhou University of Traditional Chinese MedicineNULLRecruiting1880Both1:30;2:30;Phase 4China
2ChiCTR2100050865
2020-07-182021-09-05Observation on the efficacy of Tripterygium wilfordii polyglycosides tablets combined with Adamumab in the treatment of rheumatoid arthritisA multicenter, prospective, observational study to evaluate the efficacy and safety of Tripterygium wilfordii polyglycosides combined with Adamumab in the treatment of rheumatoid arthritis rheumatoid arthritisGroup 1:Tripterygium wilfordii polyglycoside tablets + Adamu monoclonal antibody;Group 2:Methotrexate tablets + Adamu monoclonal antibody;The Second Affiliated Hospital of Guizhou University of Traditional Chinese MedicineNULLRecruiting1880BothGroup 1:30;Group 2:30;Phase 4China
3NCT04136262
(ClinicalTrials.gov)
November 25, 201921/10/2019Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid ArthritisTripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled TrialRheumatoid ArthritisDrug: Tripterygium wilfordii Hook F (TwHF);Drug: Methotrexate;Other: Dummy Tripterygium wilfordii Hook F (TwHF)Guang'anmen Hospital of China Academy of Chinese Medical SciencesNULLRecruitingN/AN/AFemale300Phase 2/Phase 3China
4NCT03589833
(ClinicalTrials.gov)
May 14, 20195/7/2018Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RAEffectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid ArthritisArthritis, RheumatoidDrug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: YisaipuPeking Union Medical College HospitalNULLCompleted18 Years65 YearsAll504Phase 4China
5NCT03337815
(ClinicalTrials.gov)
October 28, 201722/10/2017A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid ArthritisA 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction ModelRheumatoid ArthritisDrug: Treatment of MTX and TwHF placebo;Drug: Treatment of TwHF and MTX placeboGuang'anmen Hospital of China Academy of Chinese Medical SciencesNULLRecruiting45 Years70 YearsAll264Phase 2/Phase 3China
6NCT01613079
(ClinicalTrials.gov)
May 20124/6/2012Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid ArthritisEvaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.Arthritis, RheumatoidDrug: Tripterygium wilfordii Hook F;Drug: MethotrexatePeking Union Medical College HospitalNULLCompleted18 Years65 YearsBoth201Phase 2/Phase 3China
7NCT02818361
(ClinicalTrials.gov)
April 201215/6/2016Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid ArthritisTopical Tripterygium Wilfordii Gel for Treatment in Patients With Moderate Activity Rheumatoid ArthritisArthritis, RheumatoidDrug: Topical tripterygium gel;Drug: Placebo gelGuang'anmen Hospital of China Academy of Chinese Medical SciencesNULLCompleted18 Years65 YearsAll70N/AChina
8NCT01961505
(ClinicalTrials.gov)
October 201123/9/2013Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid ArthritisA Randomized Controlled Study to Determine the Effects and Safety of Topical Compound Tripterygium Wilfordii Hook F in Patients With Active Rheumatoid Arthritis.Active Rheumatoid ArthritisDrug: Topical compound tripterygium;Drug: PlaceboGuang'anmen Hospital of China Academy of Chinese Medical SciencesNULLCompleted18 Years65 YearsAll70N/ANULL
9NCT00062465
(ClinicalTrials.gov)
June 20035/6/2003Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or SulfasalazineA 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid ArthritisRheumatoid ArthritisDrug: TwHFNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLCompletedN/AN/ABoth157Phase 2United States

66. IgA nephropathy


Clinical trials : 275 Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ITMCTR2100004723
2021-04-102021-04-10A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathyA multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy IgA nephropathyKunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Hydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo;Peking University First HospitalNULLRecruiting18BothKunxian capsule group:65;Hydroxychloroquine group:65;Placebo group:65;China
2ChiCTR2100045306
2021-04-102021-04-10A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathyA multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy IgA nephropathyHydroxychloroquine group:Hydroxychloroquine and Kunxian capsule placebo;Kunxian capsule group:Kunxian capsule and Hydroxychloroquine placebo;Placebo group:Kunxian capsule and Hydroxychloroquine placebo;Peking University First HospitalNULLRecruiting18BothHydroxychloroquine group:65;Kunxian capsule group:65;Placebo group:65;China
3NCT02187900
(ClinicalTrials.gov)
June 201422/6/2014Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. fIgA NephropathyDrug: Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Drug: Mycophenolate mofetil (MMF)Second Xiangya Hospital of Central South UniversityNULLRecruiting16 Years65 YearsBoth300Phase 3China
4ChiCTR-TRC-12002228
2012-06-152012-02-03The Clinical Study on the Dispelling Wind-dampness of IgA NephropathyThe Clinical Study on the Dispelling Wind-dampness of the chronic nephropathy: The Clinical Study on the Dispelling Wind-dampness of IgA Nephropathy(Multi-center, double-blind, randomized, controlled clinical trial program) IgA NephropathyTreatment group:IgA nephropathy side (granules)+TWP tablet;Control group:Chinese medicine simulation granules + The Tripterygium simulation piece;Hangzhou Hospital of Traditional Chinese MedicineNULLCompleted1665BothTreatment group:114;Control group:114;China
5ChiCTR-OPN-16010028
2011-01-012016-11-23Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuriaEffects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria IgA nephropathyPrednisone (PRE) group:1mg/kg prednisone once daily;conventional-dose TW (CTW) group:60 mg TW daily;double-dose TW (DTW) group:?????120mg;Yancheng Third People's HospitalNULLCompleted2154BothPrednisone (PRE) group:10;conventional-dose TW (CTW) group:10;double-dose TW (DTW) group:10;NULL
6NCT00885547
(ClinicalTrials.gov)
March 200920/4/2009Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal UrinalysisProspective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.IgA NephropathyDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLTerminated18 Years60 YearsBoth90N/AChina

67. Polycystic kidney disease


Clinical trials : 221 Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00801268
(ClinicalTrials.gov)
November 200825/11/2008Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney DiseaseRandomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Polycystic KidneyDrug: tripterygium wilfordii;Drug: EmodinZhi-Hong Liu, M.D.NULLTerminated15 Years70 YearsBoth300N/AChina

96. Crohn disease


Clinical trials : 2,442 Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02044952
(ClinicalTrials.gov)
January 201419/1/2014Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction RemissionProspective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction RemissionInflammatory Bowel Diseases;Crohn's Disease;Gastrointestinal Diseases;Digestive System Diseases;Intestinal DiseasesDrug: Mesalazine, Tripterygium glycosidesZhu WeimingNULLRecruiting18 Years75 YearsBoth40Phase 2/Phase 3China
2NCT01820247
(ClinicalTrials.gov)
December 201225/3/2013Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction RemissionEfficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction RemissionCrohn's DiseaseDrug: enteral nutrition;Drug: Tripterygium glycosidesZhu WeimingNULLRecruiting18 Years75 YearsBoth100N/AChina

162. Pemphigoid


Clinical trials : 90 Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-12003592
2011-08-012012-12-30Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin Diseases Bullous pemphigoidTripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.;Institute of dermatology, Chinese Academy of Medical SciencesNULLCompleted18BothTripterygium glycosides group:100;Nicotinamide plus Minocycline group:100;China

222. Primary nephrotic syndrome


Clinical trials : 310 Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ITMCTR2200006490
2022-08-012022-08-15Evaluation of clinical effect of compound Shelong Capsule on urinary protein in membranous nephropathyEvaluation of clinical effect of compound Shelong Capsule on urinary protein in membranous nephropathy Idiopathic membranous nephropathyThe treatment group:Compound Snake Dragon capsule;The control group:Tripterygium wilfordii polyglycoside tablet;Shanxi Hospital of Traditional Chinese MedicineNULLPending1665BothThe treatment group:60;The control group:60;china
2ChiCTR2200056304
2022-04-292022-02-03Efficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with Tacrolimus Therapy in primary membranous nephropathy with moderate risk: A double-blind, randomised, controlled trialEfficacy and safety of Tripterygium Hypoglaucum Root Tablet combined with Tacrolimus Therapy in primary membranous nephropathy with moderate risk: A double-blind, randomised, controlled trial primary membranous nephropathy with moderate riskcontrol group:tacrolimus combined with placebo;Experimental group:tacrolimus combined with Colquhounia Root Tablets;The First Affiliated Hospital, College of Medicine, Zhejiang UniversityNULLPending4575Bothcontrol group:60;Experimental group:60;Phase 4China
3ChiCTR2100048382
2021-07-012021-07-06Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical TrialEfficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial Idiopathic membranous nephropathyExperimental group:On the basis of ACEI/ARB, tripterygium wilfordii polyglycoside tablets were added;Control group:The original dose of ACEI/ARB was used for treatment;Department of Nephrology, Sichuan Provincial People's HospitalNULLRecruiting1865BothExperimental group:18;Control group:18;N/AChina
4ITMCTR2200005709
2021-07-012021-07-06Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical TrialEfficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial Idiopathic membranous nephropathyExperimental group:On the basis of ACEI/ARB, tripterygium wilfordii polyglycoside tablets were added;Control group:The original dose of ACEI/ARB was used for treatment;Department of Nephrology, Sichuan Provincial People's HospitalNULLRecruiting1865BothExperimental group:18;Control group:18;N/AChina
5ChiCTR2000037467
2020-12-312020-08-28Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathyThe complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy idiopathic membranous nephropathyGold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement;
Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ;
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese MedicineNULLPending1880BothTarget condition:40;Difficult condition:40China
6NCT01161459
(ClinicalTrials.gov)
June 201012/7/2010Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus SteroidResearch Institute of Nephrology, Jinling HospitalIdiopathic Membranous NephropathyDrug: Tripterygium wilfordii;Drug: FK506Zhi-Hong Liu, M.D.NULLCompleted18 Years65 YearsBoth100N/AChina
7NCT00801463
(ClinicalTrials.gov)
January 20092/12/2008Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisPrednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisProteinuria;Focal Segmental GlomerulosclerosisDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLCompleted18 Years60 YearsBoth67N/AChina
8NCT00518219
(ClinicalTrials.gov)
July 200716/8/2007To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)To Compare the Efficacy and Safety of TW vs Valsartan in the MNMembranous NephropathyDrug: TWNanjing University School of MedicineNULLCompleted18 Years65 YearsBoth68Phase 4China

224. Purpura nephritis


Clinical trials : 16 Drugs : 43 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 58
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02878018
(ClinicalTrials.gov)
September 201617/8/2016Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura NephritisCohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura NephritisHenoch-Schonlein Purpura NephritisDrug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula;Drug: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressantLiaoning University of Traditional Chinese MedicineFirst Hospital of China Medical University;Shengjing HospitalActive, not recruiting5 Years18 YearsAll600China
2NCT03591471
(ClinicalTrials.gov)
September 20149/12/2014Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep TreatmentDemonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome DifferentiationHenoch-Schönlein Purpura NephritisDrug: Glycosides Of Tripterygium Wilfordii Hook(GTW);Drug: Sulfotanshinone Sodium Injection;Drug: Chinese herbs based on syndrome differentiation;Drug: Prednisone Acetate Tablets;Drug: Benazepril Hydrochloride Tablets;Drug: Low Molecular Weight Heparin Calcium Injection;Drug: Dipyridamole Tab 25 MG;Drug: Chinese medicine placeboHenan University of Traditional Chinese MedicinePeking University First Hospital;Children's Hospital of Fudan University;Shanghai Children's Hospital;Chengdu University of Traditional Chinese Medicine;Affiliated Hospital of Yunnan University of Traditional Chinese MedicineUnknown status2 Years18 YearsAll500Phase 1/Phase 2China

271. Ankylosing spondylitis


Clinical trials : 574 Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-11001193
2011-01-012011-02-22Tripterygium wilfordii tablets in the treatment of active ankylosing spondylitis: a randomized double-blind, placebo-controlled clinical trialTripterygium wilfordii tablets in the treatment of active ankylosing spondylitis: a randomized double-blind, placebo-controlled clinical trial ankylosing spondylitisTreatment group: tripterygium wilfordii tablets ;Control group:Placebo;Jiangsu Provincial Hospital of Traditional Chinese MedicineNULLCompleted1860BothTreatment group:66;Control group:22;China
2NCT00889694
(ClinicalTrials.gov)
October 200827/4/2009Clinical Study of Tripterygium Capsule to Treat Early Ankylosing SpondylitisClinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis: a 12-Week, Multiple Centers, Randomized Double-Blind, Positive Drug and Placebo Controlled Clinical TrialEarly Ankylosing SpondylitisDrug: Tripterygium;Drug: Sulfasalazine;Drug: placeboSun Yat-sen UniversityNULLEnrolling by invitation18 Years65 YearsBoth80Phase 2/Phase 3NULL